Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ongoing technological developments in antibody detection and characterisation allowing relative quantitation of HLA-specific antibody levels, combined with crossmatch results, now allow a graded assessment of patient potential donor immunological risk for allotransplantation, rather than a simple 'positive' or 'negative' categorization of crossmatch results. These developments have driven a thorough revision of the British Society for Histocompatibility & Immunogenetics and British Transplantation Society Guidelines for the Detection and Characterisation of Clinically Relevant Antibodies in Allotransplantation. These newly published revised Guidelines contain a number of recommendations as to best practice for antibody detection and crossmatching for the transplantation of a wide range of solid organs and tissues. These recommendations are briefly summarized in this article.

Original publication

DOI

10.1111/j.1744-313X.2010.00955.x

Type

Journal article

Journal

Int J Immunogenet

Publication Date

12/2010

Volume

37

Pages

435 - 437

Keywords

Antibodies, HLA Antigens, Histocompatibility Testing, Humans, Islets of Langerhans Transplantation, Kidney Transplantation, Liver Transplantation, Organ Transplantation, Transplantation, Homologous